Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes

Antonio R Anzueto, Gary T. Ferguson, Greg Feldman, Kenneth Chinsky, Allan Seibert, Amanda Emmett, Katharine Knobil, Dianne O'Dell, Christopher Kalberg, Glenn Crater

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Prevention and treatment of COPD exacerbations are recognized as key goals in disease management. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of fluticasone propionate/salmeterol 250 mcg/50 mcg (FSC 250/50) and salmeterol 50 mcg (SAL) twice-daily on moderate/severe exacerbations. Subjects received treatment with FSC 250/50 during a one month run-in, followed by randomization to FSC 250/50 or SAL for 52 weeks. Moderate/severe exacerbations were defined as worsening symptoms of COPD requiring antibiotics, oral corticosteroids and/or hospitalization. In 797 subjects with COPD (mean FEV1 0.98L, 34 predicted normal), treatment with FSC 250/50 significantly reduced the annual rate of moderate/severe exacerbations by 30.4 compared with SAL (1.10 and 1.59 per subject per year, respectively, p < 0.001), the annual rate of exacerbations requiring oral corticosteroids by 34 (p < 0.001) and the annual rate of moderate/severe exacerbations requiring hospitalization by 36 (p 0.043). Clinical improvements observed during run-in treatment with FSC 250/50 were better maintained over 52 weeks with FSC 250/50 compared to SAL. Statistically significant reductions in albuterol use, dyspnea scores, and nighttime awakenings and numerical benefits on quality of life were seen with FSC 250/50 compared with SAL. The incidence of adverse events was similar across groups. Pneumonia was reported more frequently with FSC 250/50 compared with SAL (7 vs. 2). FSC 250/50 is more effective than SAL at reducing the rate of moderate/severe exacerbations. These data confirm the beneficial effect of FSC on the management of COPD exacerbations and support the use of FSC in patients with COPD.

Original languageEnglish (US)
Pages (from-to)320-329
Number of pages10
JournalCOPD: Journal of Chronic Obstructive Pulmonary Disease
Volume6
Issue number5
DOIs
StatePublished - 2009

Fingerprint

Chronic Obstructive Pulmonary Disease
Adrenal Cortex Hormones
Hospitalization
Albuterol
Therapeutics
Disease Management
Random Allocation
Salmeterol Xinafoate Drug Combination Fluticasone Propionate
Salmeterol Xinafoate
Dyspnea
Multicenter Studies
Pneumonia
Quality of Life
Anti-Bacterial Agents
Incidence

Keywords

  • Chronic obstructive pulmonary disease (COPD)
  • Exacerbations
  • Fluticasone propionate
  • Inhaled corticosteroid
  • Long-acting beta2-agonist
  • Salmeterol

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. / Anzueto, Antonio R; Ferguson, Gary T.; Feldman, Greg; Chinsky, Kenneth; Seibert, Allan; Emmett, Amanda; Knobil, Katharine; O'Dell, Dianne; Kalberg, Christopher; Crater, Glenn.

In: COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 6, No. 5, 2009, p. 320-329.

Research output: Contribution to journalArticle

Anzueto, AR, Ferguson, GT, Feldman, G, Chinsky, K, Seibert, A, Emmett, A, Knobil, K, O'Dell, D, Kalberg, C & Crater, G 2009, 'Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes', COPD: Journal of Chronic Obstructive Pulmonary Disease, vol. 6, no. 5, pp. 320-329. https://doi.org/10.1080/15412550903140881
Anzueto, Antonio R ; Ferguson, Gary T. ; Feldman, Greg ; Chinsky, Kenneth ; Seibert, Allan ; Emmett, Amanda ; Knobil, Katharine ; O'Dell, Dianne ; Kalberg, Christopher ; Crater, Glenn. / Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. In: COPD: Journal of Chronic Obstructive Pulmonary Disease. 2009 ; Vol. 6, No. 5. pp. 320-329.
@article{dabf362139e04bfea98815ebe2613174,
title = "Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes",
abstract = "Prevention and treatment of COPD exacerbations are recognized as key goals in disease management. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of fluticasone propionate/salmeterol 250 mcg/50 mcg (FSC 250/50) and salmeterol 50 mcg (SAL) twice-daily on moderate/severe exacerbations. Subjects received treatment with FSC 250/50 during a one month run-in, followed by randomization to FSC 250/50 or SAL for 52 weeks. Moderate/severe exacerbations were defined as worsening symptoms of COPD requiring antibiotics, oral corticosteroids and/or hospitalization. In 797 subjects with COPD (mean FEV1 0.98L, 34 predicted normal), treatment with FSC 250/50 significantly reduced the annual rate of moderate/severe exacerbations by 30.4 compared with SAL (1.10 and 1.59 per subject per year, respectively, p < 0.001), the annual rate of exacerbations requiring oral corticosteroids by 34 (p < 0.001) and the annual rate of moderate/severe exacerbations requiring hospitalization by 36 (p 0.043). Clinical improvements observed during run-in treatment with FSC 250/50 were better maintained over 52 weeks with FSC 250/50 compared to SAL. Statistically significant reductions in albuterol use, dyspnea scores, and nighttime awakenings and numerical benefits on quality of life were seen with FSC 250/50 compared with SAL. The incidence of adverse events was similar across groups. Pneumonia was reported more frequently with FSC 250/50 compared with SAL (7 vs. 2). FSC 250/50 is more effective than SAL at reducing the rate of moderate/severe exacerbations. These data confirm the beneficial effect of FSC on the management of COPD exacerbations and support the use of FSC in patients with COPD.",
keywords = "Chronic obstructive pulmonary disease (COPD), Exacerbations, Fluticasone propionate, Inhaled corticosteroid, Long-acting beta2-agonist, Salmeterol",
author = "Anzueto, {Antonio R} and Ferguson, {Gary T.} and Greg Feldman and Kenneth Chinsky and Allan Seibert and Amanda Emmett and Katharine Knobil and Dianne O'Dell and Christopher Kalberg and Glenn Crater",
year = "2009",
doi = "10.1080/15412550903140881",
language = "English (US)",
volume = "6",
pages = "320--329",
journal = "COPD: Journal of Chronic Obstructive Pulmonary Disease",
issn = "1541-2555",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes

AU - Anzueto, Antonio R

AU - Ferguson, Gary T.

AU - Feldman, Greg

AU - Chinsky, Kenneth

AU - Seibert, Allan

AU - Emmett, Amanda

AU - Knobil, Katharine

AU - O'Dell, Dianne

AU - Kalberg, Christopher

AU - Crater, Glenn

PY - 2009

Y1 - 2009

N2 - Prevention and treatment of COPD exacerbations are recognized as key goals in disease management. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of fluticasone propionate/salmeterol 250 mcg/50 mcg (FSC 250/50) and salmeterol 50 mcg (SAL) twice-daily on moderate/severe exacerbations. Subjects received treatment with FSC 250/50 during a one month run-in, followed by randomization to FSC 250/50 or SAL for 52 weeks. Moderate/severe exacerbations were defined as worsening symptoms of COPD requiring antibiotics, oral corticosteroids and/or hospitalization. In 797 subjects with COPD (mean FEV1 0.98L, 34 predicted normal), treatment with FSC 250/50 significantly reduced the annual rate of moderate/severe exacerbations by 30.4 compared with SAL (1.10 and 1.59 per subject per year, respectively, p < 0.001), the annual rate of exacerbations requiring oral corticosteroids by 34 (p < 0.001) and the annual rate of moderate/severe exacerbations requiring hospitalization by 36 (p 0.043). Clinical improvements observed during run-in treatment with FSC 250/50 were better maintained over 52 weeks with FSC 250/50 compared to SAL. Statistically significant reductions in albuterol use, dyspnea scores, and nighttime awakenings and numerical benefits on quality of life were seen with FSC 250/50 compared with SAL. The incidence of adverse events was similar across groups. Pneumonia was reported more frequently with FSC 250/50 compared with SAL (7 vs. 2). FSC 250/50 is more effective than SAL at reducing the rate of moderate/severe exacerbations. These data confirm the beneficial effect of FSC on the management of COPD exacerbations and support the use of FSC in patients with COPD.

AB - Prevention and treatment of COPD exacerbations are recognized as key goals in disease management. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of fluticasone propionate/salmeterol 250 mcg/50 mcg (FSC 250/50) and salmeterol 50 mcg (SAL) twice-daily on moderate/severe exacerbations. Subjects received treatment with FSC 250/50 during a one month run-in, followed by randomization to FSC 250/50 or SAL for 52 weeks. Moderate/severe exacerbations were defined as worsening symptoms of COPD requiring antibiotics, oral corticosteroids and/or hospitalization. In 797 subjects with COPD (mean FEV1 0.98L, 34 predicted normal), treatment with FSC 250/50 significantly reduced the annual rate of moderate/severe exacerbations by 30.4 compared with SAL (1.10 and 1.59 per subject per year, respectively, p < 0.001), the annual rate of exacerbations requiring oral corticosteroids by 34 (p < 0.001) and the annual rate of moderate/severe exacerbations requiring hospitalization by 36 (p 0.043). Clinical improvements observed during run-in treatment with FSC 250/50 were better maintained over 52 weeks with FSC 250/50 compared to SAL. Statistically significant reductions in albuterol use, dyspnea scores, and nighttime awakenings and numerical benefits on quality of life were seen with FSC 250/50 compared with SAL. The incidence of adverse events was similar across groups. Pneumonia was reported more frequently with FSC 250/50 compared with SAL (7 vs. 2). FSC 250/50 is more effective than SAL at reducing the rate of moderate/severe exacerbations. These data confirm the beneficial effect of FSC on the management of COPD exacerbations and support the use of FSC in patients with COPD.

KW - Chronic obstructive pulmonary disease (COPD)

KW - Exacerbations

KW - Fluticasone propionate

KW - Inhaled corticosteroid

KW - Long-acting beta2-agonist

KW - Salmeterol

UR - http://www.scopus.com/inward/record.url?scp=70350112427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350112427&partnerID=8YFLogxK

U2 - 10.1080/15412550903140881

DO - 10.1080/15412550903140881

M3 - Article

C2 - 19863361

AN - SCOPUS:70350112427

VL - 6

SP - 320

EP - 329

JO - COPD: Journal of Chronic Obstructive Pulmonary Disease

JF - COPD: Journal of Chronic Obstructive Pulmonary Disease

SN - 1541-2555

IS - 5

ER -